Afuco™ Anti-Human LGR5 ADCC Therapeutic Antibody (BNC101), ADCC Enhanced
Anti-LGR5 ADCC Enhanced Antibody (BNC101) is an ADCC enhanced antibody produced by our Afuco™ platform. BNC101 is a humanized monoclonal antibody targeting LGR5, that has demonstrated functional activity against Cancer Stem Cells (CSCs) from primary colorectal cancer (CRC) patient samples. In preclinical studies, BNC101 significantly reduces CSC frequency in vivo and prevents tumour re-growth in long term studies. BNC101 also increases survival and inhibits weight loss in a cachexic CRC tumour model. To date BNC101 has shown no evidence of toxicity in preliminary safety analyses.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-470CL |
| Pricing | Inquiry |
| Host | Humanized |
| Target | LGR5 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Store it under sterile conditions at -20°C upon receiving. Recommend to pack the protein into smaller quantities for optimal storage. |